PRISM Biolabs
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
PRISM BioLab develops peptide-mimetic small molecules to drug challenging protein-protein interactions using its proprietary PepMetics® platform.
Oncology
Technology Platform
PepMetics® Technology: A proprietary drug discovery platform that designs peptide mimetic small molecules using unique, stable scaffolds to mimic α-helix or β-turn peptide structures, enabling targeting of protein-protein interactions.
Opportunities
Significant opportunity lies in leveraging the validated PepMetics® platform to establish more high-value partnerships targeting PPIs in oncology, immunology, and neurology, and advancing internal or co-developed assets into later-stage clinical trials.
Risk Factors
Key risks include clinical failure of lead assets like E7386, dependence on collaboration partners for funding and development execution, and intense competition in the PPI inhibitor space from other platform companies and modalities.
Competitive Landscape
PRISM competes with other companies targeting PPIs, such as Nimbus Therapeutics, FogPharma, and Ensemble Therapeutics. Its differentiation is its large, diverse PepMetics® compound library and proven ability to generate clinical candidates from its scaffold-based mimetic approach.